References
Januschowski K, Dimopoulos S, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Bevacizumab Study Group Venous Occlusion, Meyer CH, Szurman GB (2015) Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study. Acta Ophthalmol 93:e400–e402
Szurman GB, Januschowski K, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Dimopoulos S, Bevacizumab Study Group Venous Occlusion, Meyer CH (2016) Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicentre study. Acta Ophthalmol [Epub ahead of print]. doi:10.1111/aos.12976
Januschowski K, Feltgen N, Pielen A, Spitzer B, Rehak M, Spital G, Dimopoulos S, Bevacizumab Study Group Venous Occlusion, Meyer CH, Szurman GB (2016) Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-016-3471-22016
Epstein DL, Algvere PV, von Wendt G et al (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Szurman, G.B., Meyer, C.H., Feltgen, N. et al. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 255, 1045–1046 (2017). https://doi.org/10.1007/s00417-017-3618-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-017-3618-9